drugset
drugset / Trial / NCT02153099

Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of ENV8058 (TAK-058) in Healthy Participants

NCT02153099 ↗

Phase 1 Completed 48 enrolled Takeda
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to characterize the safety and tolerability profile of escalating dose levels of ENV8058 (TAK-058) solution when administered as a single oral dose in healthy adults.

Timeline

Start
2014-06
Primary completion
2014-11
Completion
2014-11

Drugs

EvaluationDrugModalityDoseRoute
Subject TAK-058 Unknown 5 mg Oral
Subject TAK-058 Unknown 15 mg Oral
Subject TAK-058 Unknown 30 mg Oral
Subject TAK-058 Unknown 45 mg Oral
Subject TAK-058 Unknown 75 mg Oral
Subject TAK-058 Unknown 150 mg Oral

Indications

No indication recorded.